U.S. markets open in 5 minutes
  • S&P Futures

    3,921.00
    +17.25 (+0.44%)
     
  • Dow Futures

    31,577.00
    +156.00 (+0.50%)
     
  • Nasdaq Futures

    12,076.25
    +35.75 (+0.30%)
     
  • Russell 2000 Futures

    1,782.00
    +12.20 (+0.69%)
     
  • Crude Oil

    110.88
    +1.31 (+1.20%)
     
  • Gold

    1,824.90
    +0.10 (+0.01%)
     
  • Silver

    21.17
    -0.00 (-0.01%)
     
  • EUR/USD

    1.0534
    -0.0052 (-0.50%)
     
  • 10-Yr Bond

    3.2130
    +0.0190 (+0.59%)
     
  • Vix

    26.86
    -0.37 (-1.36%)
     
  • GBP/USD

    1.2219
    -0.0051 (-0.41%)
     
  • USD/JPY

    136.1520
    +0.7060 (+0.52%)
     
  • BTC-USD

    20,986.58
    -244.61 (-1.15%)
     
  • CMC Crypto 200

    458.95
    -2.84 (-0.62%)
     
  • FTSE 100

    7,338.81
    +80.49 (+1.11%)
     
  • Nikkei 225

    27,049.47
    +178.20 (+0.66%)
     

MediciNova's Alcohol Use Disorder Candidate Reduces Alcohol Craving, Odds Of Heavy Drinking

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

MediciNova Inc (NASDAQ: MNOV) announced that secondary analysis of the Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) was published in the journal Alcoholism: Clinical and Experimental Research.

  • The publication describes a secondary analysis of a two-week clinical trial of MN-166 (ibudilast) that enrolled 52 non-treatment-seeking participants with AUD.

  • Initial findings showed that MN-166 (ibudilast), a neuroimmune modulator, reduces rates of heavy drinking and measures of alcohol craving.

  • The drug did not significantly alter mean levels of stimulation or sedation and moderated the effect of daily stimulation on the same-day number of drinks consumed (p=0.045).

  • Ibudilast attenuated alcohol-induced increases in craving compared with placebo (p=0.047) but no other subjective response measures.

  • MN-166 (ibudilast) may reduce the acute and chronic proinflammatory effects of alcohol.

  • Among individuals without withdrawal-related dysphoria, MN-166 (ibudilast) significantly tempered daily alcohol-induced changes in an urge to drink (p=0.021) and positive mood (p=0.001).

  • In January, MediciNova received a Notice of Intention to Grant from the European Patent Office for a pending patent application covering MN-166 (ibudilast) for alcohol use disorder.

  • Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2037.

  • The allowed claims cover a wide range of dosage strengths and dosing regimens of MN-166 alone and in combination with other agents.

  • Price Action: MNOV shares are up 4.64% at $3.05 during the market session on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.